DataM Intelligence analyzes hereditary angioedema treatments and markets

DataM Intelligence has published a comprehensive analysis of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent swelling episodes. The report details the disease's epidemiology, current treatment landscape, and market size, projecting future trends.

HAE results from a deficiency or dysfunction of the C1-inhibitor protein and is estimated to affect approximately one in 50,000 to 150,000 people worldwide. The report reviews approved treatments, including plasma-derived C1-INH concentrates such as Berinert and Cinryze, and recombinant C1-INH (Ruconest). It also covers kallikrein inhibitors like Kalbitor and bradykinin B2 receptor blockers like Firazyr.

The market analysis indicates the global HAE market was valued at approximately $3.14 billion in 2024 and is expected to experience significant growth. This expansion is attributed to advancements in drug development, leading to more effective and convenient treatment options, alongside improved diagnostic rates. The report highlights emerging therapies in the pipeline, such as Garadacimab and Sebetralstat, which target both acute attack management and long-term prophylaxis.

Furthermore, the analysis identifies persistent unmet needs in HAE care, including the demand for improved preventive therapies, safe options for pediatric and pregnant populations, and reduced diagnostic delays. High treatment costs and access barriers also remain significant challenges. DataM Intelligence's report offers insights for pharmaceutical companies and healthcare providers focused on advancing HAE therapeutics.